



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/757,346	01/14/2004	Heinrich Kladders	I/1447	3492
28501	7590	01/11/2006	EXAMINER	
MICHAEL P. MORRIS BOEHRINGER INGELHEIM CORPORATION 900 RIDGEURY ROAD P. O. BOX 368 RIDGEFIELD, CT 06877-0368			BUNIN, ANDREW M	
		ART UNIT		PAPER NUMBER
		3743		
DATE MAILED: 01/11/2006				

Please find below and/or attached an Office communication concerning this application or proceeding.

Tattn

Office Action Summary	Application No.	Applicant(s)	
	10/757,346	KLADDERS ET AL.	
	Examiner	Art Unit	
	Andrew M. Bunin	3743	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-22 is/are pending in the application.
 - 4a) Of the above claim(s) 11-22 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-10 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on 14 January 2004 is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date: _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date: _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

Applicant's election without traverse of claims 1-10 in the reply filed on 10/19/05 is acknowledged.

Priority

Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

Specification

The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant's use.

Arrangement of the Specification

As provided in 37 CFR 1.77(b), the specification of a utility application should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase "Not Applicable" should follow the section heading:

- (a) TITLE OF THE INVENTION.
- (b) CROSS-REFERENCE TO RELATED APPLICATIONS.
- (c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT.
- (d) THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT
- (e) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC (See 37 CFR 1.52(e)(5) and MPEP 608.05. Computer program listings (37 CFR 1.96(c)), "Sequence Listings" (37 CFR 1.821(c)), and tables having more than 50 pages of text are permitted to be submitted on compact discs.) or
REFERENCE TO A "MICROFICHE APPENDIX" (See MPEP § 608.05(a). "Microfiche Appendices" were accepted by the Office until March 1, 2001.)
- (f) BACKGROUND OF THE INVENTION.
 - (1) Field of the Invention.

(2) Description of Related Art including information disclosed under 37 CFR 1.97 and 1.98.

- (g) BRIEF SUMMARY OF THE INVENTION.
- (h) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S).
- (i) DETAILED DESCRIPTION OF THE INVENTION.
- (j) CLAIM OR CLAIMS (commencing on a separate sheet).
- (k) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet).
- (l) SEQUENCE LISTING (See MPEP § 2424 and 37 CFR 1.821-1.825. A "Sequence Listing" is required on paper if the application discloses a nucleotide or amino acid sequence as defined in 37 CFR 1.821(a) and if the required "Sequence Listing" is not submitted as an electronic document on compact disc).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-7, 9, and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hochrainer et al. (US 5947118) in view of Datta et al. (US 5871010). Hochrainer et al. disclose an inhaler for the administration of a pharmaceutical composition comprising a mouthpiece 12, an air channel opening into the mouthpiece and a chamber 9 with an air inlet channel wherein the inhaler is capable of receiving a capsule with a composition (see Figure 6). Hochrainer et al. doesn't disclose at least part of the inner surface of the mouthpiece and/or of the air channel and/or optionally the chamber contains elevations and/or depressions with a height/depth of from 0.1 to 100 microns. However, Datta et al. teach an inhaler apparatus with modified surfaced for enhanced release of dry

powders. Datta et al. disclose the surface of the substrate and the mouthpiece as having elevations and depressions with a depth of one micron to about 2.5 microns (column 2, lines 15-44), which meets the claimed range of 0.1 to 100 microns. Therefore, it would have been obvious to a person having ordinary skill in the art at the time of the invention to modify the device of Hochrainer et al. with the depressions taught by Datta et al. in order to decrease the area of contact between the selected medicaments.

As for claim 2, Hochrainer et al. has disclosed a mouthpiece 12 with an inner surface and a chamber 9 but doesn't disclose either the inner surface of the mouthpiece, the air channel and/or the chamber is produced by microtechnology or nanotechnology over at least 20% of its surface. The claimed phrase "produced by microtechnology or nanotechnology over at least 20% of its surface" is being treated as a product by process limitation. As set forth in MPEP 2113, product by process claims are NOT limited to manipulations of the recited steps, only to the structure implied by the steps. Once a product appearing to be substantially the same or similar is found, a 35 USC 103 rejection may be made and the burden is shifted to applicant to show an unobvious difference. See MPEP 2113.

Thus, even though Hochrainer et al. is silent as to the process used to produce the inner surface of the mouthpiece, air channel and/or the chamber, it appears that the product in Hochrainer et al. would be the same or similar as that claimed.

As for claim 3, Datta et al. disclose the elevations and depressions are separated by spacings of 2 microns, which reads inside the range from 0.1 to 200 microns. Therefore, it would have been obvious to a person having ordinary skill in the art at the time of the invention to modify the device of Hochrainer et al. with the spacings taught by Datta et al. in order to decrease the area of contact between the selected medicaments.

As for claim 4, although Hochrainer et al. doesn't explicitly disclose the inner surfaces as being formed by hydrophobic materials selected from one or more of glass, ceramics, metals and plastics, wherein the plastics are further selected from one or more of polyethylene, polypropylene, polycarbonate, polyacrylate, polyester and silanes. It would be inherent that the device of Hochrainer et al. be made of some type of plastic, glass, ceramic, and/or metal since it has been held that it is well known in the art that inhalers be made with a one or a combination of these materials. In addition, Datta et al. has taught an inhaler being made with a combination of metal and ceramic such as alumina ceramic (column 7, lines 10-15). Lastly, it is noted that applicant's specification does not set forth this feature, as unexpectedly providing any new result or unexpectedly solving any new problem in the art over the prior art. Accordingly, the examiner considers the selection of such to be mere obvious matter of design choice and as such does not patently distinguish the claim over the prior art, barring a convincing showing of evidence to the contrary.

In regards to claim 5, Hochrainer et al. has disclosed an inner surface but doesn't disclose the inner surfaces as being formed by processes comprising subtractive or additive treatment selected from stamping, etching, laser ablation, galvanic machining, adhesively attaching a structured film, adhesion of a powder, spraying with suspensions, and depositing sublimates. As set forth in MPEP 2113, product by process claims are NOT limited to manipulations of the recited steps, only to the structure implied by the steps. Once a product appearing to be substantially the same or similar is found, a 35 USC 103 rejection may be made and the burden is shifted to applicant to show an unobvious difference. See MPEP 2113.

Thus, even though Hochrainer et al. is silent as to the process used to produce the inner surfaces, it appears that the product in Hochrainer et al. would be the same or similar as that claimed.

As for claims 6 and 7, Hochrainer et al. inherently disclose a Bernoulli inhaler. In addition, the applicant has admitted that Bernoulli inhalers are prior art (paragraph 3, lines 4-7). Hochrainer et al. continue to disclose the inhaler comprising a capsule chamber 9, which is connected to the air channel opening in the mouthpiece 10. The

Claim 8 is rejected under 35 U.S.C. 103(a) as being unpatentable over Hochrainer et al. and Datta et al. in view of Kladders (US 4889114). Hochrainer et al. has disclosed everything except the capsule chamber as having a diameter 1.1 to 2.5 times the capsule diameter and a length 1.02 to 2 times the length of the capsule.

However, Hochrainer et al. has taught that the capsule chamber needs to have a diameter large enough to hold the capsule (column 1, lines 19-21). Kladders discloses a similar powder inhaler with a capsule chamber 6 with a diameter 1.1 to 2.5 times the capsule diameter and a length 1.03 to 2 times the length of the capsule (column 2, lines 10-19). Therefore, it would have been obvious to a person having ordinary skill in the art at the time of the invention to modify the device of Hochrainer et al. and Datta et al. with the capsule chamber diameter and length as taught by Kladders in order for the capsule to fit in the chamber in order to be completely effective within the system.

In regards to claims 9 and 10, Hochrainer et al. disclose the inhaler as having a cutting device, which is fitted with at least two sharp spikes, the spikes are capable of being inserted through openings into the capsule chamber (column 3, lines 5-9). Hochrainer et al. continue to disclose an inhaler comprising a cup-shaped lower part 6 open at the top, a plate 8 that covers the opening of the lower part 6 and perpendicularly to which is formed the capsule chamber, a button 10 movable counter to a spring on the capsule chamber, comprising two sharp spikes for opening the capsule, an upper part 13 with the mouthpiece 12 and the air channel which connects the mouthpiece 12 to the capsule chamber 9 so as to be able to convey a powder or liquid or aerosol, and a lid, these elements being joined together by a common hinge element such that they can be moved back and forth relative to one another (column 3, lines 15-18).

Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: US 5857456, US 6591833, US 6488027, US 3991761, US 4778054, and US 6669960

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Andrew M. Bunin whose telephone number is (571)272-4801. The examiner can normally be reached on Monday - Friday, 8 am - 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Henry Bennett can be reached on (571)272-4791. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


AMB
1/9/06